迈特康卓生物科技有限公司
Shaanxi Mitokondrion Biotech Co.

迈特康卓”是一家专注于线粒体医学研究的创新型企业，我们的名字“迈特康卓”源于“线粒体”（Mitochondria）的音译，承载着我们对线粒体健康领域的深度追求与坚定信念。 公司成立于2022年8月5日。公司与西安交通大学线粒体生物医学研究所紧密合作，基于研究团队“线粒体营养素“特色理论和学术研究积累，持续研发转发线粒体营养素小分子（如HTHB等）药物及医美、健康产品，打造健康衰老的卓越方案，为线粒体相关疾病的早期发现和防治提供健康产品支持。

Our name “迈特康卓” is derived from the transliteration of “Mitochondria,” symbolizing our deep pursuit and firm belief in the field of mitochondrial health. We closely partnered with the Institute of Mitochondrial Biology and Medicine (IMBM) of Xi’an Jiaotong University, specializing in the field of mitochondrial biomedicine. Established on August 5, 2022, our primary research focuses on the study and treatment of mitochondrial-related diseases and functional disorders, providing comprehensive support for early detection, intervention, and treatment of diseases. Additionally, Meitkangzhuo adheres to the theory of “mitochondrial nutrients,” continuously developing small molecule drugs, medical aesthetics, and health products, aiming to create outstanding solutions for healthy aging, allowing everyone to embrace every stage of life in their optimal state.